Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone implant added to anti-VEGF for resistant neovascular age-related macular degeneration
ACTRN12618001102268Phase 4Completed
- Sponsor
- AOU Sassari
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexamethasone, ranibizumab and aflibercept in exudative macular degeneration and Subretinal neovascularization (2 arms), sponsored by AOU Sassari. Primary endpoint: Complete regression of intraretinal/subretinal fluid. Started Feb 2016; status: completed.
02
Drugs
dexamethasoneranibizumabaflibercept
03
Conditions
exudative macular degenerationSubretinal neovascularization
Beyond the preview
Go deeper on ACTRN12618001102268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001102268.